Clinical Trial Update: Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects [EARLY_Phase 1]

View source ↗

Summary

Hepion Pharmaceuticals reports completion of a single-dose ADME study of [14C]-Rencofilstat in healthy male subjects, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis with Fibrosis

Drugs mentioned

• Rencofilstat (rencofilstat)

Snippet

Sponsor: Hepion Pharmaceuticals, Inc. | Conditions: NASH With Fibrosis | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2024-10-03